TEPYLUTE

Growth

thiotepa

NDAINTRAVENOUSSOLUTION
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1

Mechanism of Action

Alkylating Activity

Pharmacologic Class:

Alkylating Drug

Clinical Trials (1)

NCT00238433Phase 2Completed

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Started Mar 2005
37 enrolled
Lymphoma

Loss of Exclusivity

LOE Date
Aug 16, 2041
188 months away
Patent Expiry
Aug 16, 2041

Patent Records (1)

Patent #ExpiryTypeUse Code
11975013
Aug 16, 2041
Product
—
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers